(Q40681408)
Statements
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) (English)
Amie S Corbin
Eric P Stoffregen
Michael W Deininger
1 December 2002